正清风痛宁片治疗IgA肾病中等量蛋白尿的疗效

Efficacy of Zhengqiang Fengtongning Tablets in the treatment of IgA nephropathy with moderate amount of proteinuria

目的：研究正清风痛宁片治疗IgA肾病中等量蛋白尿的临床疗效。方法选择156例IgA肾病中等量蛋白尿患者（尿蛋白定量1～3 g/24 h），按入院顺序号的奇偶数分组，正清风痛宁片联合缬沙坦治疗组（观察组）78例，缬沙坦治疗组（对照组）78例。治疗剂量：正清风痛宁片每次2片，3次/d，缬沙坦治疗80 mg，1次/d，服药并观察12个月，比较两组患者临床缓解率以及24 h尿蛋白定量、血肌酐、血浆白蛋白、总蛋白、血脂等临床指标的变化，并观察临床不良反应。结果观察12个月，观察组临床缓解率高于对照组，分别为87．2％和56．4％（P＜0．01）；观察组24 h尿蛋白定量为（0．42±0．36）g/24 h，明显低于对照组[（1．59±0．66）g/24 h]，两组相比差异有统计学意义（P＜0．05）；血浆白蛋白和总蛋白、血肌酐水平、血脂水平以及临床不良反应两组对比差异无统计学意义。结论正清风痛宁片联合缬沙坦治疗IgA肾病中等量蛋白尿，临床缓解率高于单纯缬沙坦治疗，能更有效降低24 h尿蛋白定量，无明显不良反应。

Objective To study the safety and efficacy of Zhengqiang Fengtongning Tablets in the treatment of IgA nephropa-thy with moderate amount of proteinuria.Methods 156 patients with IgA nephropathy with moderate amount of proteinuria （ urine pro-tein quantitation：1-3 g/24 h） were randomly divided into two groups.The study group was given Zhengqiang Fengtongning Tablets with valsartan and control group was given valsartan alone for treatment.The dosage of Zhengqiang Fengtongning was 2 tablets, 3 times a day, and valsartan was 80 mg/day.Results After treatment for 6 months, the total effective rate in the study group was significantly higher than that in the control group（ 87.2%vs 56.4%, P〈0.01）.24 h urinary protein in the study group was significantly lower than that in the control group（1.59 ±0.66, P〈0.05）.There were no differences in serum albumine, serum creatinine （Scr） , total protein （ TP） , total cholesterol （ TC） , and incidence of adverse reactions between the two groups.Conclusions Zhengqiang Feng-tongning Tablets combined with valsartan for the treatment of IgA nephropathy with moderate amount of proteinuria is safe and reliable, which is worthy of clinical application.